FDA-Approved Bioidentical Hormones vs. Compounded Bioidentical HRT: What’s the Difference?

FDA-approved bioidentical hormones and compounded bioidentical hormone therapy (BHRT) are not the same. “Bioidentical” describes a hormone’s molecular structure—not its FDA approval, safety, effectiveness, or quality. FDA-approved estradiol and micronized progesterone are bioidentical hormones that undergo regulatory evaluation for safety, effectiveness, manufacturing quality, and labeling. Compounded hormones may have a legitimate role when a patient’s medical needs cannot be met by an approved product, but they are not automatically safer, more natural, or more effective.

Understanding this distinction is essential when considering women’s hormone replacement therapy at Azani Medical Spa in Bethlehem, Pennsylvania.

At a Glance: FDA-Approved vs. Compounded Bioidentical Hormones

Feature	FDA-Approved Bioidentical Hormones	Compounded Bioidentical Hormones
Molecular structure	May be identical to naturally produced human hormones	May contain identical hormones
FDA approval	Approved products undergo FDA review	Compounded preparations are not FDA-approved
Safety and effectiveness	Evaluated for specific indications and formulations	Not evaluated by FDA before marketing as finished products
Manufacturing quality	Subject to FDA manufacturing and quality requirements	Requirements depend on the compounding pathway; generally different from FDA-approved manufacturing
Dose consistency	Standardized approved strengths and formulations	Quality and potency may vary depending on preparation and compounding practices
Clinical evidence	Established evidence for approved indications	Generally less robust evidence for specific compounded formulations
Package labeling	Standardized labeling, including applicable warnings	May lack the FDA-approved product labeling and standardized warnings
Customization	Available approved strengths and delivery forms	Can be customized for specific patient needs
Preferred when appropriate?	Generally preferred when an appropriate approved formulation exists	Reserved for situations where an approved product cannot adequately meet a patient’s medical need

What Does “Bioidentical” Actually Mean?

Bioidentical hormones have the same molecular structure as hormones produced naturally by the human body.

For example:

• Estradiol is a bioidentical form of estrogen.
• Micronized progesterone is bioidentical progesterone.
• FDA-approved estradiol and progesterone products can be bioidentical.

The term does not mean the hormone is risk-free, natural in origin, or automatically superior.

A hormone’s molecular structure does not determine whether its formulation has been adequately studied, manufactured consistently, or approved for a specific medical indication.

The Endocrine Society explains that bioidentical hormones may be available in FDA-approved products as well as compounded preparations. The distinction is regulatory and pharmaceutical—not simply chemical.

Source: Endocrine Society Position Statement on Compounded Bioidentical Hormone Therapy

Which FDA-Approved Hormones Are Bioidentical?

Women may be surprised to learn that many established FDA-approved menopausal hormone therapies already contain bioidentical hormones.

FDA-approved estradiol

Estradiol is available in multiple FDA-approved formulations, including:

• Oral estradiol tablets
• Transdermal estradiol patches
• Estradiol gels and sprays
• Certain estrogen creams, vaginal tablets, inserts, and rings

These formulations differ in route of administration, systemic exposure, dosing, and clinical indications.

Transdermal estradiol delivers estrogen through the skin and avoids first-pass hepatic metabolism. This may be relevant when considering certain vascular risk factors, although route selection does not eliminate the risks associated with systemic estrogen.

FDA-approved micronized progesterone

Micronized progesterone is another bioidentical hormone available in FDA-approved formulations.

For women with an intact uterus who use systemic estrogen, an appropriate progestogen is generally required to protect the endometrium from estrogen-associated stimulation.

The type, dose, route, and duration of progestogen matter. Not every compounded progesterone cream provides reliable endometrial protection.

Why this matters

A woman does not need compounded hormones simply to obtain hormones that are molecularly identical to those produced by her body.

FDA-approved estradiol and progesterone may provide that molecular identity while offering standardized formulations and regulatory evaluation.

For FDA information about approved menopausal hormone products, see FDA Menopause: Hormone Therapy.

What Is Compounded Bioidentical Hormone Therapy?

Compounded bioidentical hormone therapy is prepared by a compounding pharmacy according to a prescription.

Compounding may involve:

• Combining different hormones
• Preparing a customized strength
• Changing the dosage form
• Using a different vehicle or inactive ingredient
• Preparing a formulation when an appropriate commercially available product is unavailable

Compounded preparations may contain estradiol, estriol, estrone, progesterone, testosterone, or combinations of hormones.

They may be supplied as capsules, creams, gels, suppositories, or other dosage forms.

Compounding has legitimate medical uses

Compounding is not inherently inappropriate.

For example, a patient may have a clinically important allergy to an ingredient in an approved medication or may require a dosage form that is not commercially available.

In such circumstances, a compounded preparation may be considered when the clinician determines that an appropriate FDA-approved alternative cannot meet the patient’s needs.

The important distinction is between patient-specific medical necessity and routine use of compounded hormones simply because they are marketed as more natural, personalized, or safer.

ACOG recommends against routinely prescribing compounded bioidentical menopausal hormone therapy when FDA-approved formulations are available.

FDA-Approved vs. Compounded BHRT: Why Quality Control Matters

One of the most important differences between FDA-approved and compounded hormone products is the regulatory pathway governing the finished preparation.

FDA-approved hormone products

Before approval, FDA evaluates a drug’s evidence for safety and effectiveness for its intended indication.

Approved products also undergo manufacturing and quality requirements designed to ensure consistent identity, strength, purity, and performance.

Their labeling includes approved indications, dosage instructions, contraindications, and relevant warnings.

Compounded hormone preparations

Compounded drugs are not FDA-approved.

FDA does not verify their safety, effectiveness, or quality before marketing as finished compounded products.

The regulatory requirements depend on how and where the product is compounded. Traditional patient-specific compounding pharmacies operate under a different framework from FDA-registered outsourcing facilities.

Some outsourcing facilities are subject to FDA inspection and current good manufacturing practice requirements. However, registration or inspection of a compounding facility does not mean that an individual compounded hormone product has FDA approval.

Source: FDA: Compounding and the FDA—Questions and Answers

Can Compounded Hormones Have Inconsistent Doses?

Yes. Variability in potency and formulation quality is a recognized concern with compounded preparations.

Studies evaluating compounded hormone products have identified variability in the amount of active ingredient, including products containing more or less hormone than indicated on the label.

Potential quality concerns include:

• Variation in active hormone concentration
• Differences between batches
• Variability in absorption
• Differences in formulation and delivery
• Potential contamination when compounding practices are inadequate

The degree of risk depends on the preparation, pharmacy, manufacturing practices, and quality controls. Not every compounded product is necessarily defective, but compounded preparations do not receive the same FDA premarket evaluation as approved finished drugs.

ACOG discusses dose variability, quality concerns, and limitations of available safety evidence in its Clinical Consensus on Compounded Bioidentical Menopausal Hormone Therapy.

Are Compounded Bioidentical Hormones Safer Than FDA-Approved HRT?

There is no convincing evidence that compounded bioidentical hormones are generally safer or more effective than FDA-approved menopausal hormone therapy.

Several common claims deserve clarification.

Claim: Compounded hormones are safer because they are natural

Molecular identity does not establish safety.

Estradiol can be bioidentical and still carry risks associated with systemic estrogen exposure.

For example, systemic estrogen may increase thromboembolic risk in some women, and estrogen without adequate endometrial protection can increase endometrial cancer risk in women with an intact uterus.

The source of the hormone does not remove these pharmacologic risks.

Claim: Customized hormones are safer because they are individualized

Individualization is important in hormone therapy, but customization does not automatically improve safety.

A customized preparation may introduce uncertainty regarding dose consistency, absorption, and the evidence supporting its particular formulation.

Individualized treatment can often be achieved using FDA-approved formulations and strengths.

Claim: Compounded hormones are more effective because they are tailored to laboratory results

There is no convincing evidence that routinely adjusting menopausal hormone doses to saliva or urine hormone measurements improves clinical outcomes.

ACOG does not recommend adjunct hormone testing to determine compounded menopausal hormone dosing because evidence supporting these practices is limited.

The primary treatment goal is usually improvement in clinically relevant menopausal symptoms, with dosing individualized according to response, safety, and established clinical considerations.

What About Salivary Hormone Testing?

Salivary testing is frequently marketed as a way to customize compounded BHRT.

However, salivary hormone concentrations do not reliably establish the hormone exposure of target tissues or provide a validated method for determining the ideal menopausal hormone dose.

Hormone concentrations vary with collection conditions, assay methods, and physiological factors.

ACOG states that adjunct hormone testing, including salivary testing, is not recommended for prescribing or dosing compounded menopausal hormone therapy because supporting evidence is insufficient.

This does not mean laboratory testing is never appropriate.

Testing may be indicated for specific clinical questions, diagnostic evaluation, or monitoring in selected circumstances. The distinction is that routine salivary testing has not been established as a reliable method for customizing menopausal hormone therapy.

Source: ACOG Compounded Bioidentical Menopausal Hormone Therapy

Why FDA-Approved Hormones Are Generally Preferred

For women who are appropriate candidates for menopausal hormone therapy, FDA-approved products generally offer several advantages:

1. Regulatory evaluation: Approved products undergo evaluation for safety and effectiveness for specific indications.
2. Standardized formulations: Available strengths and dosage forms are defined.
3. Manufacturing quality: Approved products are subject to established manufacturing and quality requirements.
4. Established labeling: Contraindications, warnings, and dosing instructions are standardized.
5. Clinical evidence: Approved formulations have evidence supporting their indicated uses.
6. Treatment selection: Multiple approved routes and formulations allow individualized therapy without routine compounding.

These advantages do not make FDA-approved hormone therapy risk-free.

The appropriate product still depends on the woman’s age, time since menopause, symptoms, medical history, uterine status, route, dose, and treatment goals.

When Might Compounded Hormone Therapy Be Appropriate?

Compounded hormone therapy may be considered when a specific medical need cannot be adequately addressed by an available FDA-approved product.

Examples may include:

• A clinically important allergy or intolerance to an ingredient in an approved formulation
• A dosage form that is not commercially available and is medically necessary
• A specific formulation requirement that cannot be met by approved products

The decision should involve a qualified prescriber and a discussion of the limitations of the compounded preparation.

Compounding should not be used routinely when an appropriate FDA-approved alternative exists.

Special Considerations: Progesterone Cream, Pellets, and Custom Hormone Mixtures

Progesterone creams

Some compounded progesterone creams are promoted for menopause symptoms or endometrial protection.

However, topical progesterone creams may have variable absorption and are not established as reliable endometrial protection for women receiving systemic estrogen.

Women with an intact uterus should not assume that a compounded progesterone cream adequately protects against estrogen-associated endometrial hyperplasia.

Hormone pellets

Hormone pellets may provide prolonged hormone exposure, but they can be difficult or impossible to remove completely once implanted.

Potential concerns include prolonged exposure, difficulty adjusting doses, and limited long-term safety evidence for certain compounded pellet regimens.

ACOG recommends avoiding testosterone pellet therapy for menopausal indications because of limited safety data and the inability to readily reverse treatment.

Custom mixtures

Combining multiple hormones does not necessarily improve outcomes.

Each ingredient should have an appropriate clinical indication, supporting evidence, and a favorable individual benefit-risk assessment.

How Should Women Choose a BHRT Provider?

When considering menopause hormone therapy, women should ask:

• Is the recommended hormone FDA-approved?
• Is the hormone bioidentical, synthetic, or a combination?
• What is the specific clinical indication?
• Why is this formulation preferred over available FDA-approved options?
• Is the dose supported by clinical evidence?
• Does treatment require endometrial protection?
• Are laboratory tests being used for a valid clinical purpose?
• What are the potential benefits, risks, alternatives, and monitoring requirements?
• What is the plan if treatment does not improve symptoms or causes adverse effects?

A medically responsible consultation should explain the difference between FDA-approved and compounded preparations without suggesting that either molecular identity or customization guarantees superior outcomes.

Dr. Monica Gavin, MD: Evidence-Based BHRT at Azani Medical Spa

At Azani Medical Spa in Bethlehem, Pennsylvania, Dr. Monica Gavin emphasizes individualized menopause care, informed decision-making, and evidence-based discussions of hormone therapy.

Understanding the difference between FDA-approved bioidentical hormones and compounded preparations helps women make informed decisions about symptom management, safety, and treatment options.

The objective is not to prescribe the most customized or heavily marketed hormone formulation. It is to identify an appropriate treatment strategy based on medical history, symptoms, clinical evidence, and individual needs.

Azani Medical Spa – Bethlehem, PA

Dr. Monica Gavin, MD

• Women’s Hormone Replacement Therapy
• Request a Consultation
• Phone: 610-625-3000
• Text: 610-625-3002
• Address: 2551 Baglyos Circle, Suite A18, Bethlehem, PA 18020

Medical Disclaimer

This article is for educational purposes only and does not replace individualized medical evaluation, diagnosis, or treatment. Hormone therapy decisions should be made with a qualified healthcare professional after reviewing personal medical history, symptoms, risks, and treatment goals.

Last reviewed: November 2026